Novo Nordisk gets 2.0 mg Ozempic dose approved in US

The pharmaceutical firm expects to launch 2.0 mg doses of Ozempic in the US during the second quarter of 2022.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by catherine brett

The US Food and Drug Administration (FDA) has approved Ozempic in a 2.0 mg dose for the treatment of adults with type 2 diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading